Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe bone marrow to unlock secrets of childhood leukemia

NCT ID NCT05792007

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at bone marrow cells from children with acute leukemia and compares them to cells from children without blood diseases. The goal is to understand why some leukemias relapse or resist treatment. Researchers will measure how these cells use energy and handle stress, which may reveal new ways to fight the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could reveal why some children's leukemia resists treatment, pointing toward new drug targets.
What could go wrong
This is an early observational study with only 40 participants, so findings may not apply broadly or lead directly to new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 15 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * for patients with AL: 1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis 2. Not having received prior hematological treatment 3. Aged 1 to 15 years old 4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened. 5. Affiliated patient or beneficiary of a social security scheme. * Control group patients: 1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis). 2. Aged between 1 and 15 years old. 3. Having no pathology of hematological origin. 4. Not having received any treatment that could interfere with the functioning of the bone marrow. 5. Whose 2 parents or the holder of parental authority have signed a consent enlightened. 6. Affiliated patient or beneficiary of a social security scheme. Exclusion Criteria: * for patients with AL: 1. Patient under 1 year old and over 15 years old. 2. Contraindication to myelogram. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia. 5. Having received prior hematological treatments. 6. Parents with physical or mental condition not allowing to understand the informed consent. * Control group patients 1. Patient under 1 year old and over 15 years old. 2. Having an underlying haematological pathology. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Having received prior hematological treatments. 5. Parents with physical or mental condition not allowing to understand informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoid leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia childhood acute myeloid leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoid leukemia Acute myeloid leukemia in children

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service d'hématologie biologique-CHRU TOURS

    NOT_YET_RECRUITING

    Tours, 37044, France

  • Service d'onco-hématologie pédiatrique -CHRU Tours

    RECRUITING

    Tours, 37044, France

  • Service de chirurgie orthopédique pédiatrique -CHRU TOURS

    RECRUITING

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.